Displaying drugs 501 - 525 of 9619 in total
Misoprostol
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.[L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the...
Approved
Matched Iupac: … methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate …
Matched Description: … [A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] …
Matched Description: … [A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] …
Cedazuridine
Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated.[A215082, A215092, A215097] Hypomethylating agents such as decitabine and azacitidine are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous...
Approved
Investigational
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Iupac: … 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide …
Matched Description: … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ... was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27 …
Matched Description: … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ... was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27 …
Fezolinetant
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Matched Iupac: … 5-[(8R)-7-(4-fluorobenzoyl)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-3-methyl-1,2,4-thiadiazole …
Matched Description: … [A259591,A259542] NK3, one of the receptors expressed in KNDy neurons, is activated by neurokinin B and ... regulator in generating Gonadotropin-releasing hormone (GnRH) pulse through the kisspeptin, neurokinin B, ... estrogen levels during menopause will decrease the estrogen-mediated feedback loop and increase neurokinin B …
Matched Categories: … Neurokinin 3 Receptor Antagonist …
Matched Description: … [A259591,A259542] NK3, one of the receptors expressed in KNDy neurons, is activated by neurokinin B and ... regulator in generating Gonadotropin-releasing hormone (GnRH) pulse through the kisspeptin, neurokinin B, ... estrogen levels during menopause will decrease the estrogen-mediated feedback loop and increase neurokinin B …
Matched Categories: … Neurokinin 3 Receptor Antagonist …
Chlordiazepoxide
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Approved
Illicit
Investigational
Sotagliflozin
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Iupac: … (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(methylsulfanyl)oxane-3,4,5-triol …
Matched Description: … with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 …
Matched Description: … with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Iupac: … ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3( …
Posaconazole
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Approved
Investigational
Vet approved
Matched Iupac: … )piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one ... 4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-[(1H-1,2,4-triazol-1-yl)methyl]oxolan-3-yl]methoxy}phenyl …
Ulobetasol
Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.[L15047,L15052,L15102]
Ulobetasol was granted FDA approval on 17 December 1990.
Approved
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Matched Iupac: … 4-[(1E)-2-{5,5,8,8-tetramethyl-3-[(1H-pyrazol-1-yl)methyl]-5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl] …
Delandistrogene moxeparvovec
Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading...
Approved
Investigational
Matched Description: … Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta ... [A260261]
Delandistrogene moxeparvovec comprises a non-replicating, recombinant adeno-associated virus …
Setmelanotide
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Iupac: … 7S,10S,13R,16S,19R,22R)-13-benzyl-22-[(2S)-5-[(diaminomethylidene)amino]-2-acetamidopentanamido]-10-{3- ... [(diaminomethylidene)amino]propyl}-16-[(1H-imidazol-5-yl)methyl]-7-[(1H-indol-3-yl)methyl]-19-methyl- …
Pyrantel
Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis .
Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic amidines with suitable pharmacokinetic properties (specifically, duration of action) for use...
Approved
Vet approved
Matched Products: … KONTIL 250 MG ÇIĞNEME TABLETI, 3 ADET …
Capsaicin
Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent...
Approved
Matched Iupac: … (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide …
Matched Mixtures name: … Med O-3 Bio- …
Matched Products: … Omega 3 ... Omega 3 Heat Therapy …
Matched Mixtures name: … Med O-3 Bio- …
Matched Products: … Omega 3 ... Omega 3 Heat Therapy …
Ambrosia artemisiifolia pollen
Ambrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … 3-ragweed Mix, Giant/short/western Pollen …
Estetrol
Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms. Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception. It is more potent and...
Approved
Investigational
Matched Salts cas: … 2055649-81-3 …
Ferric maltol
Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Iupac: … iron(3+) tris(2-methyl-4-oxo-4H-pyran-3-olate) …
Matched Description: … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability …
Matched Description: … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability …
Nabumetone
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Technetium Tc-99m nofetumomab merpentan
Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma...
Approved
Withdrawn
Matched Description: … [A32115] The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety …
Flurandrenolide
A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
Approved
Ketorolac
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain,...
Approved
Matched Products: … ROSUPREN INYECTABLE AL 3% (30 MG/ML) I.M …
Regorafenib
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Iupac: … 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide …
Matched Description: … FDA approved on September 27, 2012. …
Matched Description: … FDA approved on September 27, 2012. …
Displaying drugs 501 - 525 of 9619 in total